Philadelphia, PA
Chelation Therapy clinics in Philadelphia
Chelation therapy in Philadelphia is offered by a small set of integrative and naturopathic clinics, typically for documented heavy metal toxicity. Referral and testing pathways often interact with Penn Medicine, Jefferson Health, Temple Health, and CHOP when lab confirmation is needed. Local demand is shaped by a dense academic-medicine and healthcare-industry population, and clinics vary in whether they push short detox courses or longer TACT-modeled cardiovascular protocols.
FDA-approved agents for specific poisoning diagnoses include calcium disodium EDTA, DMSA, and deferoxamine. Chelation for cardiovascular disease or autism is not FDA-approved and has caused deaths when the wrong EDTA form is used. Pennsylvania rules on delegation, collaborative practice, and compounding shapes which providers can deliver chelation and under what supervision.
With verified chelation clinics on Regenerated.com in Philadelphia, Pennsylvania, patients can compare provider credentials, testing protocols, and whether the clinic uses calcium disodium EDTA (the correct form) or the dangerous disodium EDTA. ACAM-trained MDs with documented pre-treatment heavy metal testing are the minimum bar.
Regulatory context
A note on Pennsylvania's chelation therapy rules.
The FDA has approved a narrow set of chelating agents for specific heavy metal toxicities. Calcium disodium edetate (CaNa2EDTA, Versenate) is approved for symptomatic lead poisoning, succimer (Chemet, DMSA) for pediatric lead poisoning at blood lead levels above 45 mcg/dL, deferoxamine (Desferal) and deferasirox (Exjade) for chronic iron overload, and dimercaprol (BAL) for arsenic, gold, and acute lead poisoning. Use of EDTA chelation for cardiovascular disease was studied in the NIH-funded TACT trial (2013) with controversial findings and remains not FDA-approved for that indication. Chelation for autism spectrum disorder is not evidence-based and has been linked to pediatric deaths. The FDA issued a 2010 sweep of warning letters to compounders marketing OTC chelation products with unapproved disease claims.
-
Pennsylvania Medical Practice Act of 1985, 63 P.S. Section 422
Governs MD practice in Pennsylvania. -
Pennsylvania Osteopathic Medical Practice Act, 63 P.S. Section 271
Governs DO practice in Pennsylvania.
Pennsylvania is the location of the 2005 Pittsburgh pediatric chelation death, in which a five-year-old autistic boy died after receiving Na2EDTA (the wrong EDTA salt) instead of CaNa2EDTA. This case shaped national board guidance on chelation safety and pediatric protocols. The Pennsylvania State Board of Medicine has investigated chelation practitioners for marketing claims tied to autism and cardiovascular disease. Pennsylvania does not license NDs. Philadelphia and Pittsburgh have moderate integrative medicine communities.
Chelation Therapy in Philadelphia, answered.
Explore related care